{"product_id":"syrs-vrio-analysis","title":"Syros Pharmaceuticals, Inc. (SYRS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Syros Pharmaceuticals, Inc. (SYRS)'s market strength with this sharp VRIO Analysis. We distill whether its current assets truly translate into a sustainable competitive advantage by rigorously testing their Value, Rarity, Inimitability, and organizational alignment. Dive in now to see the definitive assessment of Syros Pharmaceuticals, Inc. (SYRS)'s core capabilities and what truly sets it apart from the competition.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 1: Proprietary Gene Control Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of Syros Pharmaceuticals, Inc. (SYRS) - the Proprietary Gene Control Platform - at a critical juncture. Honestly, the platform itself represents decades of foundational science, but the organization’s current structure means its value is trapped, not being actively exploited for growth right now. We need to assess what this technology is worth on paper versus what the current corporate reality allows it to achieve.\u003c\/p\u003e\n\n\u003ch\u003eValue: Scientific Foundation and Market Potential\u003c\/h\u003e\n\u003cp\u003eThe platform provides the scientific bedrock for all their past and potential future drug candidates by precisely regulating gene expression. This is valuable because it targets the regulatory genome, allowing them to address targets previously considered undruggable. For instance, the potential market for their lead candidate, tamibarotene, in high-risk Myelodysplastic Syndromes (MDS) with RARA overexpression was projected to be over $800 million in the U.S. by 2029, illustrating the platform's potential value generation capacity.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Unique Genomic Integration\u003c\/h\u003e\n\u003cp\u003eWhat makes this platform rare in the small-to-mid-cap biotech sector is its specific integration of disease biology and genomic data into a drug discovery engine. It was built on the groundbreaking discovery of Super-Enhancers, which are key regulatory regions of the genome. This deep focus on the regulatory genome, rather than just the protein-coding genes, sets it apart from many peers.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Scientific Know-How and Data Moat\u003c\/h\u003e\n\u003cp\u003eReplicating this platform is tough because it relies on deep, proprietary scientific know-how and massive, accumulated data sets derived from years of research. Competitors can’t just buy the software; they need the institutional knowledge to apply it effectively to find novel, highly targeted treatments. It’s a time-consuming process to build that scientific depth from scratch.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Structure for Preservation, Not Expansion\u003c\/h\u003e\n\u003cp\u003eHere’s the quick math on the current state: Syros Pharmaceuticals enacted a 94% workforce reduction, expected to be complete by December 6, 2024, following the failure of the SELECT-MDS-1 trial. Furthermore, the company voluntarily delisted from Nasdaq around March 20, 2025, and is deregistering with the SEC. This means the organization is currently structured for preservation or asset sale, not for the aggressive clinical development needed to fully exploit the platform’s potential. What this estimate hides is the near-total dismantling of the operational structure that once supported the platform.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary Lock-in\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage is currently Temporary. The platform’s inherent scientific value is effectively locked away until a strategic buyer or a major licensing deal materializes. Without the organization actively funding and driving pipeline progression - which they are not, given the wind-down - the advantage is dormant. The latest reported cash position of $58.3 million as of September 30, 2024, was guided to fund operations into Q3 2025, suggesting a finite window for any strategic transaction before assets are fully liquidated.\u003c\/p\u003e\n\n\u003cp\u003eHere is the summary of the VRIO assessment for this core capability:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eImplication for Advantage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003ePotential for high returns, evidenced by market projections (e.g., $800M+ potential for one asset).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eUnique focus on the regulatory genome and Super-Enhancer science.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eNo (Costly\/Difficult)\u003c\/td\u003e\n\u003ctd\u003eHigh scientific know-how and accumulated data make replication slow.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003ctd\u003eSeverely hampered by workforce reduction (94%) and delisting\/deregistration plans.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eValue is latent; requires an external acquirer or licensee to activate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe key takeaway is that the technology is strong, but the corporate structure is not organized to capture that strength currently. Finance: prepare a sensitivity analysis on the platform's salvage value based on a potential sale price per preclinical asset by next Wednesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 2: Remaining Cash Reserves Under Lender Oversight\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 2: Remaining Cash Reserves Under Lender Oversight\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis is the primary resource now, funding the orderly wind-down and maximizing stakeholder value. Cash and cash equivalents as of September 30, 2024, were \u003cstrong\u003e$58.3 million USD\u003c\/strong\u003e. Projections indicated funding operations into \u003cstrong\u003eQ3 2025\u003c\/strong\u003e. The net loss for Q3 2024 was \u003cstrong\u003e$6.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount (as of Q3 2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHaving any cash runway after a major Phase 3 failure and loan default is rare for a company in this position. The company enacted a \u003cstrong\u003e94%\u003c\/strong\u003e workforce reduction. The company reported zero revenue for Q3 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eNet Loss Q3 2023: \u003cstrong\u003e$40.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Loss Q3 2024: \u003cstrong\u003e$6.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCash is fungible, but the terms under which the remaining funds were managed (via the Oxford Finance budget) are unique to Syros Pharmaceuticals, stemming from the forbearance agreement following a loan default. The debt to Oxford Finance was settled on February 28, 2025, for approximately \u003cstrong\u003e$6 million\u003c\/strong\u003e in cash and non-cash assets. A previous partial payment toward the debt was \u003cstrong\u003e$33.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is explicitly structured to exploit this by limiting expenditures and executing the wind-down plan. The company secured a forbearance agreement with Oxford Finance after defaulting on a loan. The company maintains a current ratio of \u003cstrong\u003e2.25\u003c\/strong\u003e following the debt settlement. The Nasdaq Global Select Market compliance deadline was set for \u003cstrong\u003eJuly 7, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eWorkforce Reduction: \u003cstrong\u003e94%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDebt Settlement Amount: Approximately \u003cstrong\u003e$6 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio: \u003cstrong\u003e2.25\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained (for the duration of the wind-down). This controlled cash preservation is the current, singular focus of the executive team. The cash runway was projected into \u003cstrong\u003eQ3 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 3: SY-1365 (Selective CDK7 Inhibitor Asset)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e Development of SY-1365 was discontinued in October \u003cstrong\u003e2019\u003c\/strong\u003e to prioritize the oral CDK7 inhibitor, SY-5609. The analysis below reflects the asset's status at the time of discontinuation and historical data.\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eIt represented a non-divested, potentially high-value small molecule asset for solid tumors and hematologic malignancies, demonstrating proof-of-mechanism in a Phase 1 trial. The asset was studied in patients with a median of five prior therapies.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eSelective CDK7 inhibition is a specific, high-interest target area; SY-1365 was the \u003cstrong\u003efirst\u003c\/strong\u003e selective CDK7 inhibitor to enter clinical development. The dose escalation portion of the Phase 1 trial treated 32 patients.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe specific compound structure and associated preclinical data were protected by Syros Pharmaceuticals' IP. Preclinical studies showed anti-tumor activity in models of ovarian and breast cancers. The highest dose tested was 112 mg\/m².\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eExploitation was discontinued in October \u003cstrong\u003e2019\u003c\/strong\u003e. The company's current focus, as of Q3 \u003cstrong\u003e2024\u003c\/strong\u003e, is on tamibarotene.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe advantage was \u003cstrong\u003etemporary\u003c\/strong\u003e; it demonstrated proof-of-mechanism but was discontinued due to an unfavorable profile compared to the oral candidate, SY-5609.\u003c\/p\u003e\n\u003cp\u003eThe following table provides relevant financial context for Syros Pharmaceuticals as of the latest reported period, Q3 \u003cstrong\u003e2024\u003c\/strong\u003e:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Guidance\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ3 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSY-1365 clinical trial data points included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDose selected for expansion: \u003cstrong\u003e80 mg\/m²\u003c\/strong\u003e twice-weekly (single agent).\u003c\/li\u003e\n\u003cli\u003eCDK7 occupancy greater than \u003cstrong\u003e50 percent\u003c\/strong\u003e at doses of \u003cstrong\u003e32 mg\/m²\u003c\/strong\u003e and higher.\u003c\/li\u003e\n\u003cli\u003eMedian of five prior therapies for treated patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 4: Intellectual Property Covering Platform Technology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The patents and know-how covering the Syros Platform IP provide a defensive moat around their core scientific approach, separate from specific drug compositions.\u003c\/p\u003e\n\u003cp\u003eThe Syros Platform is defined as proprietary gene control platform for the discovery and development of small molecule therapeutics, consisting of:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eRegulatory genomics capabilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eDisease biology capabilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eSmall molecule transcriptional chemistry capabilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAlgorithms, databases of regulatory genomes, and compound structure discovery technologies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe maintenance of this IP involves recurring financial commitments; the cumulative cost to maintain a single U.S. patent for its full term is estimated at $14,470 in official fees alone.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Patents covering a proprietary discovery engine are inherently rare, as they represent years of focused R\u0026amp;D investment.\u003c\/p\u003e\n\u003cp\u003eSpecific data points related to the patent portfolio:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eSyros' grant share as of January 2024 was 24%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Asset Type\u003c\/th\u003e\n\u003cth\u003eIdentifier\/Date Reference\u003c\/th\u003e\n\u003cth\u003eAssociated Financial\/Statistical Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued U.S. Patent Example\u003c\/td\u003e\n\u003ctd\u003eU.S. Patent No. 10,106,526 (Covers SY-1365 related compositions)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Specific patent term data not found)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Patent Application Example 1\u003c\/td\u003e\n\u003ctd\u003eUS20240034742A1 (Filed February 1, 2024)\u003c\/td\u003e\n\u003ctd\u003eRelates to Dosing regimens for CDK7 inhibitors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Patent Application Example 2\u003c\/td\u003e\n\u003ctd\u003eUS20230310325A1 (Filed October 5, 2023)\u003c\/td\u003e\n\u003ctd\u003eRelates to High surface-area lyophilized compositions comprising arsenic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Patent rights are legally protected, making direct imitation impossible without licensing or expiration.\u003c\/p\u003e\n\u003cp\u003eThe company's market capitalization as of October 24, 2024, was $55.5M.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The IP is maintained through legal filings, which is a standard, though currently minimal, operational function.\u003c\/p\u003e\n\u003cp\u003eOperational financial context related to IP sustainment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities as of June 30, 2022, were $86.3 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash reserves were stated to provide funding runway into Q3 2025 (as of November 2024).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. As long as the patents are in force, they offer a sustained barrier to entry for platform replication.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 5: SY-2101 Preclinical Program (Gaucher Disease)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 5: SY-2101 Preclinical Program (Gaucher Disease)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This asset diversifies the portfolio beyond oncology into rare genetic diseases, offering a potential long-shot value driver if the company were to pivot or sell the program. The asset, as developed for Acute Promyelocytic Leukemia (APL), showed an oral bioavailability of approximately \u003cstrong\u003e80 percent\u003c\/strong\u003e in a dose confirmation study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having a preclinical asset in a rare disease space shows breadth in their gene control application. The development path for SY-2101 in APL involved achieving comparable pharmacokinetic exposures to IV ATO at a 15 mg dose of SY-2101 versus 0.15 mg\/kg of IV ATO.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific compound and its development pathway are proprietary. The study provided intrapatient PK crossover results directly comparing SY-2101 with ATO IV.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This program is likely subject to the same severe budget cuts as the rest of R\u0026amp;D due to the wind-down. Syros announced in October 2023 that it stopped further investment in the clinical development of SY-2101. The company announced a plan to wind down operations in February 2025. The company enacted a 94% reduction in its workforce, expected to be completed by December 6, 2024. Research and development expenses for Q3 2022 were $25.8 million, with a decrease noted due to external costs related to preclinical programs. Restructuring costs for Q3 2023 were $2.4 million. Loan obligations totaled approximately $43.7 million, with a partial repayment of $33.5 million made.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It's an early-stage asset whose value is highly speculative and dependent on external funding\/acquisition. The company's cash on last count was reported as $58m (as of November 2024).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSY-2101 Program Data Summary (APL Indication):\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral Bioavailability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80 percent\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported from dose confirmation study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSY-2101 Dose (APL Study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15 mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAchieved comparable PK to IV ATO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIV ATO Dose (APL Study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.15 mg\/kg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eComparison dose for PK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMR (AUC0-last, Fasted SY-2101 vs IV ATO)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGeometric Mean Ratio for systemic exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Q3 2022)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflected external costs for preclinical programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring Costs (Q3 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncluded asset impairment charges\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOperational Status Updates:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInvestment in SY-2101 was stopped in October 2023.\u003c\/li\u003e\n\u003cli\u003eCompany announced plan to wind down operations in February 2025.\u003c\/li\u003e\n\u003cli\u003eWorkforce reduction of 94% enacted.\u003c\/li\u003e\n\u003cli\u003eLoan default involved obligations of approximately $43.7 million.\u003c\/li\u003e\n\u003cli\u003ePartial loan repayment of $33.5 million made.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 6: Scientific Expertise in Biomarker-Driven Development\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe team’s deep knowledge in linking molecular biomarkers (like RARA overexpression) to patient response is critical for any future targeted therapy development, even if the current pipeline failed.\u003c\/p\u003e\n\u003cp\u003eThe RARA overexpression biomarker is present in approximately $\\mathbf{50\\%}$ of higher-risk myelodysplastic syndromes (HR-MDS) and $\\mathbf{30\\%}$ of acute myeloid leukemia (AML) populations.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTrial\/Regimen\u003c\/th\u003e\n\u003cth\u003ePatient Population\u003c\/th\u003e\n\u003cth\u003eComplete Response (CR) Rate\u003c\/th\u003e\n\u003cth\u003eOverall Response Rate (ORR)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 (Tamibarotene + Azacitidine)\u003c\/td\u003e\n\u003ctd\u003eRARA-positive AML (unfit)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSELECT-AML-1 (Triplet: Tamibarotene + Venetoclax + Azacitidine)\u003c\/td\u003e\n\u003ctd\u003eRARA-positive unfit AML\u003c\/td\u003e\n\u003ctd\u003eImplied $\\mathbf{100\\%}$ CR\/CRi\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSELECT-MDS-1 (Tamibarotene + Azacitidine vs. Placebo + Azacitidine)\u003c\/td\u003e\n\u003ctd\u003eRARA-positive HR-MDS (first $\\mathbf{190}$ patients)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23.8%\u003c\/strong\u003e vs. $\\mathbf{18.8\\%}$\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eIn the SELECT-AML-1 trial, the triplet regimen achieved a $\\mathbf{100\\%}$ CR\/CRi rate compared to $\\mathbf{70\\%}$ for the doublet (venetoclax and azacitidine) alone in response-evaluable patients.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThis specialized translational science skill set is not common, especially in hematologic malignancies.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eIt resides in the human capital, which is hard to copy, though key personnel may depart during a wind-down.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThis capability was central to their strategy but is now being preserved only in the minimal staff required for asset management and wind-down compliance.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSyros Pharmaceuticals had $\\mathbf{68}$ employees as of December 31, 2023.\u003c\/li\u003e\n\u003cli\u003eThe number of employees decreased by $\\mathbf{49}$ or $\\mathbf{-41.88\\%}$ compared to the previous year.\u003c\/li\u003e\n\u003cli\u003eResearch and development (R\\\u0026amp;D) expenses were $\\mathbf{\\$24.7}$ million for the first quarter of 2024, down from $\\mathbf{\\$28.8}$ million for the first quarter of 2023.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative (G\\\u0026amp;A) expenses were $\\mathbf{\\$6.3}$ million for the first quarter of 2024, down from $\\mathbf{\\$7.4}$ million for the first quarter of 2023, primarily due to a reduction in headcount and related expenses.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q1 2024 was $\\mathbf{\\$3.7}$ million, compared to a net loss of $\\mathbf{\\$23.8}$ million for Q1 2023.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities as of March 31, 2024, were $\\mathbf{\\$108.3}$ million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. It erodes quickly as key scientists leave the firm post-wind-down announcement.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 7: Collaboration Agreements (e.g., TYK2 Program)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 7: Collaboration Agreements (e.g., TYK2 Program)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Existing agreements, like the one with Takeda for the TYK2 program, provide potential, albeit reduced, future non-dilutive revenue streams or milestone payments. The termination of the Pfizer collaboration resulted in $0 revenue recognized in Q3 2024, compared to $3.8 million recognized in Q3 2023.\u003c\/p\u003e\n\u003cp\u003eRarity: Securing partnerships with major pharmaceutical companies like Takeda is a mark of external validation. The company also had a Master Collaboration Agreement with QIAGEN Manchester Limited terminated on November 13, 2024.\u003c\/p\u003e\n\u003cp\u003eImitability: The contract terms are unique, but the ability to secure such deals is not entirely inimitable. The upfront payment for a comparable TYK2 program (Takeda acquiring from Nimbus) was approximately $4 billion USD.\u003c\/p\u003e\n\u003cp\u003eOrganization: The company must maintain minimal administrative function to service these contracts through the wind-down period. Following recent developments, the company enacted a 94% reduction in its workforce, expected to be completed by December 6, 2024.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary. The value is realized only if the partner continues development and Syros Pharmaceuticals retains a royalty\/milestone right. The Trailing Twelve Month revenue as of September 30, 2024, was $386K.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCollaboration Metric\u003c\/th\u003e\n\u003cth\u003ePeriod\/Program\u003c\/th\u003e\n\u003cth\u003eFinancial\/Statistical Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Recognized (Q3)\u003c\/td\u003e\n\u003ctd\u003eQ3 2023 (Prior to Pfizer Termination)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Recognized (Q3)\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 (Post-Pfizer Termination)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Revenue\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$386K\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgreement Termination Date\u003c\/td\u003e\n\u003ctd\u003eQIAGEN Master Collaboration Agreement\u003c\/td\u003e\n\u003ctd\u003eNovember 13, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparable Industry Upfront Payment\u003c\/td\u003e\n\u003ctd\u003eTakeda Acquisition of Nimbus TYK2 Program\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$4 billion USD\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eTakeda Acquisition of Nimbus TYK2 Program\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$2 billion USD\u003c\/strong\u003e total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company's ability to secure future non-dilutive funding is contingent upon the success of its remaining pipeline assets and the execution of new business development opportunities, as evidenced by the exploration of opportunities for the SY-5609 asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe company's cash and cash equivalents as of September 30, 2024, were \u003cstrong\u003e$58.3 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nCash position is believed to be sufficient to fund operations into the \u003cstrong\u003ethird quarter of 2025\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nThe company reported a net loss of \u003cstrong\u003e$6.4 million\u003c\/strong\u003e for Q3 2024.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 8: Historical Financial Data and Regulatory Filings\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: The complete, audited financial history and SEC filings are necessary for any potential acquirer or for compliance during deregistration.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eFinancial Data Points (as of latest reported):\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$108.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eThird Quarter 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eThird Quarter 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eThird Quarter 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss per Share\u003c\/td\u003e\n\u003ctd\u003eThird Quarter 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.16\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nHistorical financial data includes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities as of \u003cstrong\u003eDecember 31, 2023\u003c\/strong\u003e: \u003cstrong\u003e$139.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for the third quarter of 2023: \u003cstrong\u003e$40.1 million\u003c\/strong\u003e, or \u003cstrong\u003e$1.43 per share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and development (R\u0026amp;D) expenses for Q3 2024: \u003cstrong\u003e$20.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative (G\u0026amp;A) expenses for Q3 2024: \u003cstrong\u003e$5.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nRegulatory filings include, but are not limited to, the Annual Report on Form 10-K for the year ended December 31, 2023, filed on \u003cstrong\u003eMarch 27, 2024\u003c\/strong\u003e, and Current Reports on Form 8-K, such as the one filed on \u003cstrong\u003eSeptember 5, 2024\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: A complete, clean set of historical data for a public company is a standard but necessary resource for M\u0026amp;A due diligence.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: The data itself is public record, but the organized internal records supporting it are a resource.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: The legal\/finance teams are tasked with organizing this data for the final wind-down and deregistration process.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: None. This is a necessary compliance function, not a source of competitive edge.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSyros Pharmaceuticals, Inc. (SYRS) - VRIO Analysis: Core Capability 9: Experience in Orderly Cessation of Operations\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 9: Experience in Orderly Cessation of Operations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: The current management's ability to execute a controlled wind-down, as approved by the Board and lender, preserves residual value better than a sudden bankruptcy.\u003c\/p\u003e\n\u003cp\u003eRarity: While not a desired capability, successfully managing a controlled shutdown is a specific, rare operational skill set in biotech.\u003c\/p\u003e\n\u003cp\u003eImitability: It relies on the specific legal agreements and the current executive team's execution.\u003c\/p\u003e\n\u003cp\u003eOrganization: The entire remaining structure is now organized around this singular, critical objective.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Sustained (for the wind-down period). This disciplined approach directly impacts the final cash distribution to creditors and shareholders.\u003c\/p\u003e\n\u003cp\u003eFinance: finalize the Q3 2025 cash projection based on the wind-down budget by Wednesday.\u003c\/p\u003e\n\u003cp\u003eThe operational context for this capability is defined by recent financial restructuring and workforce reduction following clinical trial outcomes.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (as of Sep 30, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSufficient to fund requirements into Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoan Default Obligation (Oxford Finance, LLC)\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$43.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDeclared immediately due and payable post-trial failure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartial Loan Repayment Made\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePayment made under forbearance agreement terms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e94%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImplemented as a cost-saving measure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (Pre-reduction Context)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e68\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompany headcount prior to major reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported for the quarter ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 General \u0026amp; Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease primarily due to headcount reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Research \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease from Q3 2023's $28.3 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflects termination of collaboration agreement with Pfizer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization's structure reflects the singular focus on cessation, marked by executive and board transitions:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDeparture of President and CEO Conley Chee and CFO Jason Haas, effective \u003cstrong\u003eNovember 22, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResignations of multiple directors on \u003cstrong\u003eNovember 12, 2024\u003c\/strong\u003e and \u003cstrong\u003eNovember 15, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIntention to voluntarily delist from Nasdaq and terminate SEC reporting obligations, with expected delisting around \u003cstrong\u003eMarch 20, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey financial markers indicating the transition to wind-down status:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMarket Capitalization reported as low as \u003cstrong\u003e$6.95 million\u003c\/strong\u003e or \u003cstrong\u003e$5.15M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStock trading near 52-week low of \u003cstrong\u003e$0.16\u003c\/strong\u003e as of February 25, 2025.\u003c\/li\u003e\n\u003cli\u003eFinancial health rated as WEAK with negative EBITDA of \u003cstrong\u003e-$110.18M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516259983509,"sku":"syrs-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/syrs-vrio-analysis.png?v=1740219744","url":"https:\/\/dcf-model.com\/es\/products\/syrs-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}